Blueprint Medicines Corporation (0HOJ.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 06:37PM BST
| Previous close | 109.50 |
| Open | 110.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 106.10 - 110.56 |
| 52-week range | 42.68 - 110.56 |
| Volume | |
| Avg. volume | 276 |
| Market cap | 52.609M |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -11.06 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Insider MonkeyBlueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript May 2, 2024 Blueprint Medicines Corporation misses on earnings expectations. Reported EPS is $ EPS, expectations were $-1.64. Blueprint Medicines Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. […]
ZacksBlueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
- GuruFocus.com
Blueprint Medicines Corp (BPMC) (Q1 2024) Earnings Call Transcript Highlights: Surpassing ...
Blueprint Medicines reports robust Q1 earnings, raises EBITDA outlook, and progresses in key pipeline developments.
© 2024 Yahoo. All rights reserved.